{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:47:23Z","timestamp":1782816443054,"version":"3.54.5"},"reference-count":88,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Type 2 diabetes (T2D), a major global health challenge, represents approximately 96% of all cases of diabetes worldwide. Epidemiological forecasts indicate the prevalence of this disease could rise by almost 45% over the next 25 years. T2D is a chronic metabolic disorder characterised by insulin resistance and progressive impairment of \u03b2-cell function. Untreated T2D can lead to serious microvascular and macrovascular complications. Traditional therapies have focused primarily on glycaemic control, whereas modern treatment strategies are increasingly centred on the broader pathophysiology of T2D. Among new therapeutic approaches, triazine derivatives have gained significant attention as versatile scaffolds for the development of antidiabetic drugs. This article provides a comprehensive review of triazines (mainly 1,2,4-triazines and 1,3,5-triazines) as promising compounds for the treatment of T2D and its complications. Three databases (Scopus, PubMed, and Web of Science) were searched for the period of 2000\u20132025. Over the past 25 years, numerous compounds have been described. They were primarily investigated as inhibitors of digestive enzymes and factors that cause diabetic complications. The individual sections discuss the biological activity of these compounds, focusing on SAR analysis and the studies conducted (in vitro, in silico, and in vivo). During this period, two compounds, fotagliptin and imeglimin, have entered clinical use. The results show that triazines have great potential to become antidiabetic drugs. They can not only regulate blood sugar levels (by acting on digestive enzymes, insulin secretion or glucose transport) but also directly prevent serious complications of diabetes.<\/jats:p>","DOI":"10.3390\/ph19071018","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:01:17Z","timestamp":1782813677000},"page":"1018","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Potential of Triazines as Antidiabetic Agents\u2014A Review of Structures and Pharmacological Activity"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8454-4440","authenticated-orcid":false,"given":"Dorota","family":"\u0141a\u017cewska","sequence":"first","affiliation":[{"name":"Chair of Chemical Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Strelchuk","sequence":"additional","affiliation":[{"name":"Chair of Chemical Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3674-3581","authenticated-orcid":false,"given":"Jadwiga","family":"Handzlik","sequence":"additional","affiliation":[{"name":"Chair of Chemical Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University Medical College, ul. Medyczna 9, 30-688 Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2025). IDF Diabetes Atlas, International Diabetes Federation. [11th ed.]. Available online: https:\/\/diabetesatlas.org."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"115734","DOI":"10.1016\/j.biopha.2023.115734","article-title":"Diabetes mellitus: Classification, mediators, and complications; A gate to identify potential targets for the development of new effective treatments","volume":"168","author":"Antar","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-024-01951-9","article-title":"Type 2 diabetes mellitus in adults: Pathogenesis, prevention and therapy","volume":"9","author":"Lu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"M\u0142ynarska, E., Czarnik, W., Dzie\u017ca, N., J\u0119draszak, W., Majchrowicz, G., Prusinowski, F., Stabrawa, M., Rysz, J., and Franczyk, B. (2025). Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26031094"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Liu, M., Ahmed, W.L., Zhuo, L., Yuan, H., Wang, S., and Zhou, F. (2023). Association of Sleep Patterns with Type 2 Diabetes Mellitus: A Cross-Sectional Study Based on Latent Class Analysis. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20010393"},{"key":"ref_6","first-page":"e23501","article-title":"Does Insufficient Sleep Increase the Risk of Developing Insulin Resistance: A Systematic Review","volume":"14","author":"Singh","year":"2022","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.5664\/jcsm.8026","article-title":"Association Between Late Bedtime and Diabetes Mellitus: A Large Community-Based Study","volume":"15","author":"Yan","year":"2019","journal-title":"J. Clin. Sleep Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"550","DOI":"10.5551\/jat.65551","article-title":"A Comprehensive Analysis of Diabetic Complications and Advances in Management Strategies","volume":"32","author":"Iwasaki","year":"2025","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cabr\u00e9, F., Centelles, J.J., and Cascante, M. (2025). From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17091125"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.5603\/EP.a2022.0014","article-title":"Tirzepatide\u2014A dual GIP\/GLP-1 receptor agonist\u2014A new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes","volume":"73","author":"Nowak","year":"2022","journal-title":"Endokrynol. Pol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"EVIDra2400265","DOI":"10.1056\/EVIDra2400265","article-title":"Pharmacologic Therapies for Type 2 Diabetes","volume":"4","author":"Kuo","year":"2025","journal-title":"NEJM Evid."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"135761","DOI":"10.1016\/j.ijbiomac.2024.135761","article-title":"Exploring aldose reductase inhibitors as promising therapeutic targets for diabetes-linked disabilities","volume":"280","author":"Ahmad","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00325481.2022.2060598","article-title":"Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease","volume":"135","author":"Lerma","year":"2023","journal-title":"Postgrad. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1186\/s40001-025-02697-y","article-title":"HDAC4: An emerging target in diabetes mellitus and diabetic complications","volume":"30","author":"Lin","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13813455.2021.1956976","article-title":"SIRT1: A promising therapeutic target in type 2 diabetes mellitus","volume":"130","author":"Mihanfar","year":"2024","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Artasensi, A., Pedretti, A., Vistoli, G., and Fumagalli, L. (2020). Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs. Molecules, 25.","DOI":"10.3390\/molecules25081987"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2174\/1389557513666140103111017","article-title":"1,2,3-Triazine scaffold as a potent biologically active moiety: A mini review","volume":"14","author":"Kumar","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/1389557514666140131111837","article-title":"1,2,4-triazine analogs as novel class of therapeutic agents","volume":"14","author":"Kumar","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/slct.202004591","article-title":"Recent Advances on the s-Triazine Scaffold with Emphasis on Synthesis, Structure-Activity and Pharmacological Aspects: A Concise Review","volume":"6","author":"Ganai","year":"2021","journal-title":"ChemistrySelect"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Khalid, Z., Alnuwaiser, M.A., Ahmad, H.A., Shafqat, S.S., Munawar, M.A., Kamran, K., Abbas, M.M., Kalam, M.A., and Ewida, M.A. (2022). Experimental and Computational Analysis of Newly Synthesized Benzotriazinone Sulfonamides as Alpha-Glucosidase Inhibitors. Molecules, 27.","DOI":"10.3390\/molecules27206783"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.bmcl.2017.01.094","article-title":"Synthesis, molecular docking and \u03b1-glucosidase inhibition of 2-((5,6-diphenyl-1,2,4-triazin-3-yl)thio)-N-arylacetamides","volume":"27","author":"Wang","year":"2017","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_22","first-page":"100207","article-title":"Design, synthesis, \u03b1-glucosidase inhibition and hypoglycemic activity of 3-aceto(benzo)hydrazide-1,2,4-triazines as potential anti-diabetic agents","volume":"12","author":"Valipour","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"113145","DOI":"10.1016\/j.intimp.2024.113145","article-title":"Antiglycation and anti-inflammatory potential of 1,2,4-triazine derivatives targeting AGE\u2013RAGE-mediated signaling in THP-1 monocytes","volume":"142","author":"Jahan","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zawada, A., Machowiak, A., Rychter, A.M., Ratajczak, A.E., Szymczak-Tomczak, A., Dobrowolska, A., and Krela-Ka\u017amierczak, I. (2022). Accumulation of Advanced Glycation End-Products in the Body and Dietary Habits. Nutrients, 14.","DOI":"10.3390\/nu14193982"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Zhang, Z., Tu, C., Chen, X., and He, R. (2025). Advanced Glycation End Products in Disease Development and Potential Interventions. Antioxidants, 14.","DOI":"10.3390\/antiox14040492"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103979","DOI":"10.1016\/j.bioorg.2020.103979","article-title":"Synthesis and screening of (E)-3-(2-benzylidenehydrazinyl)-5,6-diphenyl-1,2,4-triazine analogs as novel dual inhibitors of \u03b1-amylase and \u03b1-glucosidase","volume":"101","author":"Shamim","year":"2020","journal-title":"Bioorganic Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.4155\/fmc-2020-0032","article-title":"Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications","volume":"12","author":"Kumar","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13205-024-04178-1","article-title":"Exploration of leads from bis-indole based triazine derivatives targeting human aldose reductase in diabetic type 2: In-silico approaches","volume":"15","author":"Roney","year":"2025","journal-title":"3 Biotech"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"104970","DOI":"10.1016\/j.arabjc.2023.104970","article-title":"Bis-indole based triazine derivatives: Synthesis, characterization, in vitro \u03b2-glucuronidase, anti-cancer and anti-bacterial evaluation along with in silico molecular docking and ADME analysis","volume":"16","author":"Khan","year":"2023","journal-title":"Arab. J. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Hanke, J., Romejko, K., and Niemczyk, S. (2025). Sodium-Glucose Cotransporter-2 Inhibitors in Diabetes and Beyond: Mechanisms, Pleiotropic Benefits, and Clinical Use\u2014Reviewing Protective Effects Exceeding Glycemic Control. Molecules, 30.","DOI":"10.3390\/molecules30204125"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"116343","DOI":"10.1016\/j.ejmech.2024.116343","article-title":"Synthetic approaches and clinical application of small-molecule inhibitors of sodium-dependent glucose transporters 2 for the treatment of type 2 diabetes mellitus","volume":"269","author":"Xie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.5012\/bkcs.2011.32.8.2938","article-title":"1,2,4-Triazinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors","volume":"32","author":"Kang","year":"2011","journal-title":"Bull. Korean Chem. Soc."},{"key":"ref_33","unstructured":"Lee, J., Lee, S.H., Seo, H.J., Kim, M.J., Kang, S.Y., Kim, J., Lee, S.H., Jung, M.E., Son, E.J., and Song, K.S. (2013). C-Aryl Glucoside SGLT2 Inhibitors and Pharmaceutical Compositions Comprising Same. (8,541,380 B2), US Patent."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"116464","DOI":"10.1016\/j.ejmech.2024.116464","article-title":"Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)","volume":"272","author":"Shao","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_35","first-page":"1","article-title":"DPP\u20144 inhibitors in Type 2 Diabetes mellitus\u2014A Panoramic Review","volume":"2","author":"Trivedi","year":"2023","journal-title":"Int. J. Clin. Med. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1080\/17425255.2021.1915283","article-title":"Safety and pharmacokinetic interaction between fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects","volume":"17","author":"Ding","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/cpdd.895","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of a Dipeptidyl Peptidase-4 Inhibitor: A Randomized, Double-Blinded, Placebo-Controlled Daily Administration of Fotagliptin Benzoate for 14 Days for Type 2 Diabetes Mellitus","volume":"10","author":"Wu","year":"2021","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Xu, M., Sun, K., Xu, W., Wang, C., Yan, D., Li, S., Cong, L., Pi, Y., Song, W., and Sun, Q. (2023). Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: A randomized, multicenter, double-blind, placebo-controlled, phase 3 trial. BMC Med., 21.","DOI":"10.1186\/s12916-023-03089-x"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1111\/dom.16427","article-title":"Fotagliptin add-on therapy to metformin in patients with uncontrolled type 2 diabetes: A randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"27","author":"Yu","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"117643","DOI":"10.1016\/j.ejmech.2025.117643","article-title":"New drugs approved by the NMPA in 2024: Synthesis and clinical applications","volume":"291","author":"Zhao","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1021\/acs.jmedchem.3c00320","article-title":"Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4915","DOI":"10.1111\/dom.16534","article-title":"Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study","volume":"27","author":"Buckeridge","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_45","unstructured":"(2026, May 18). Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-provides-update-oral-glp-1-receptor-agonist."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"108762","DOI":"10.1016\/j.bioorg.2025.108762","article-title":"Dual \u03b1-amylase and \u03b1-glucosidase inhibitors: Recent progress from natural and synthetic resources","volume":"163","author":"Jha","year":"2025","journal-title":"Bioorganic Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e202400686","DOI":"10.1002\/slct.202400686","article-title":"Developing Correlation Between In Silico Molecular Modeling and In Vitro \u03b1-Amylase, Anti-Cancer and SARS-COV-2 Studies of Bis-Indole Derived Triazine-Based Thiazolidinone Hybrid Derivatives","volume":"9","author":"Khan","year":"2024","journal-title":"ChemistrySelect"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2300628","DOI":"10.1002\/ardp.202300628","article-title":"Synthesis, biological activities, and molecular docking studies of triazolo[4,3-b]triazine derivatives as a novel class of \u03b1-glucosidase and \u03b1-amylase inhibitors","volume":"357","author":"Seyfi","year":"2024","journal-title":"Arch. Pharm."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bioorg.2017.03.004","article-title":"Design, synthesis and anti-diabetic activity of triazolotriazine derivatives as dipeptidyl peptidase-4 inhibitors","volume":"72","author":"Patel","year":"2017","journal-title":"Bioorganic Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/S0960-894X(03)00623-1","article-title":"Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity","volume":"13","author":"Guertin","year":"2003","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/1873-3468.14901","article-title":"Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs","volume":"598","author":"Pardo","year":"2024","journal-title":"FEBS Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bioorg.2014.12.001","article-title":"Triazinoindole analogs as potent inhibitors of \u03b1-glucosidase: Synthesis, biological evaluation and molecular docking studies","volume":"58","author":"Rahim","year":"2015","journal-title":"Bioorganic Chem."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Taha, M., Alshamrani, F.J., Rahim, F., Hayat, S., Ullah, H., Zaman, K., Imran, S., Khan, K.M., and Naz, F. (2019). Synthesis of Novel Triazinoindole-Based Thiourea Hybrid: A Study on \u03b1-Glucosidase Inhibitors and Their Molecular Docking. Molecules, 24.","DOI":"10.20944\/preprints201909.0130.v1"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"103284","DOI":"10.1016\/j.bioorg.2019.103284","article-title":"New triazinoindole bearing thiazole\/oxazole analogues: Synthesis, \u03b1-amylase inhibitory potential and molecular docking study","volume":"92","author":"Rahim","year":"2019","journal-title":"Bioorganic Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1039\/D4OB01487A","article-title":"Efficient synthesis of promising antidiabetic triazinoindole analogues via a solvent-free method: Investigating the reaction of 1,3-diketones and 2,5-dihydro-3H-[1,2,4]triazino[5,6-b]indole-3-thione","volume":"23","author":"Aggarwal","year":"2025","journal-title":"Org. Biomol. Chem."},{"key":"ref_56","unstructured":"(2026, May 10). Available online: https:\/\/calculator.academy\/%CE%BCg-ml-to-%C2%B5m-calculator\/."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/jm5015814","article-title":"Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold","volume":"58","author":"Stefek","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2478\/intox-2019-0014","article-title":"General toxicity assessment of the novel aldose reductase inhibitor cemtirestat","volume":"12","author":"Karasu","year":"2019","journal-title":"Interdiscip. Toxicol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.neuroscience.2020.07.014","article-title":"Antioxidant Mechanisms in the Neuroprotective Action of Cemtirestat: Studies in Chemical Models, Liposomes and Rat Brain Cortical Slices","volume":"443","author":"Prnova","year":"2020","journal-title":"Neuroscience"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/cbf.3818","article-title":"Antioxidants in Diabetes-Induced Complications (ADIC) Study Group. Cemtirestat, an aldose reductase inhibitor and antioxidant compound, induces ocular defense against oxidative and inflammatory stress in rat models for glycotoxicity","volume":"41","author":"Reihanifar","year":"2023","journal-title":"Cell Biochem. Funct."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12640-020-00305-x","article-title":"Combatting Nitrosative Stress and Inflammation with Novel Substituted Triazinoindole Inhibitors of Aldose Reductase in PC12 Cells Exposed to 6-Hydroxydopamine Plus High Glucose","volume":"39","author":"Elmazoglu","year":"2021","journal-title":"Neurotox. Res."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Wu, T.-T., Guo, Q.-Q., Chen, Z.-L., Wang, L.-L., Du, Y., Chen, R., Mao, Y.-H., Yang, S.-G., Huang, J., and Wang, J.-T. (2020). Design, synthesis and bioevaluation of novel substituted triazines as potential dual PI3K\/mTOR inhibitors. Eur. J. Med. Chem., 204.","DOI":"10.1016\/j.ejmech.2020.112637"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s40265-021-01589-9","article-title":"Imeglimin Hydrochloride: First Approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11892-023-01531-1","article-title":"Imeglimin: The new kid on the block","volume":"24","author":"Shrestha","year":"2024","journal-title":"Curr. Diabetes Rep."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5603\/EP.a2022.0014","article-title":"Imeglimin: A new antidiabetic drug with potential for the treatment of patients with type 2 diabetes","volume":"73","author":"Nowak","year":"2022","journal-title":"Endokrynol. Pol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00228-025-03902-x","article-title":"Imeglimin systematic review: A novel therapeutic approach for type 2 diabetes\u2014Unveiling benefits on \u03b2-cell function, insulin sensitivity, and potential long-term glycaemic control (HbA1c)","volume":"81","author":"Shireen","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14740\/jem1605","article-title":"Imeglimin: Discovery, Pharmacology, and Trials","volume":"16","author":"Lonardo","year":"2026","journal-title":"J. Endocrinol. Metab."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"14501","DOI":"10.1007\/s00210-025-04198-5","article-title":"Efficacy and safety of imeglimin, a novel oral agent in the management of type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"398","author":"Tewari","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9410","DOI":"10.1038\/s41598-024-60206-3","article-title":"Synthesis and molecular docking studies of new aryl imeglimin derivatives as a potent antidiabetic agent in a diabetic zebrafish model","volume":"14","author":"Khodakhah","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_70","first-page":"100160","article-title":"Thiazolidinedione an auspicious scaffold as PPAR-\u03b3 agonist: Its possible mechanism to Manoeuvre against insulin resistant diabetes mellitus","volume":"11","author":"Basak","year":"2024","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11094-016-1416-z","article-title":"Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of novel arylidene thiazolidinedione analogs on a type 2 diabetes model","volume":"50","author":"Ahmadi","year":"2016","journal-title":"Pharm. Chem. J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.bmcl.2011.01.055","article-title":"1-((3S,4S)-4-amino-1-(4-substituted-1,3,5-triazin-2-yl) pyrrolidin-3-yl)-5,5-difluoropiperidin-2-one inhibitors of DPP-4 for the treatment of type 2 diabetes","volume":"21","author":"Andrews","year":"2011","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"83438","DOI":"10.1039\/C6RA15948F","article-title":"Sulfonamide-1,3,5-triazine\u2013thiazoles: Discovery of a novel class of antidiabetic agents via inhibition of DPP-4","volume":"6","author":"Gao","year":"2016","journal-title":"RSC Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"44186","DOI":"10.1038\/srep44186","article-title":"ENOblock, a unique small molecule inhibitor of the non-glycolytic functions of enolase, alleviates the symptoms of type 2 diabetes","volume":"7","author":"Cho","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/cb300687k","article-title":"A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes","volume":"8","author":"Jung","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/0929867043455927","article-title":"Sorbitol dehydrogenase: Structure, function and ligand design","volume":"11","author":"Darmanin","year":"2004","journal-title":"Curr. Med. Chem."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1021\/jm020288y","article-title":"A Sorbitol Dehydrogenase Inhibitor of Exceptional in Vivo Potency with a Long Duration of Action: 1-(R)-{4-[4-(4,6-Dimethyl[1,3,5]triazin-2-yl)-2R,6S-dimethylpiperazin-1-yl]pyrimidin-2-yl}ethanol","volume":"45","author":"Mylari","year":"2002","journal-title":"J. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0960-894X(02)00208-1","article-title":"SAR and species\/stereo-selective metabolism of the sorbitol dehydrogenase inhibitor, CP-470,711","volume":"12","author":"Ballinger","year":"2002","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1177\/0091270009336354","article-title":"Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of a Novel Sorbitol Dehydrogenase Inhibitor in Healthy Participants","volume":"50","author":"Landau","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1016\/S0968-0896(03)00490-5","article-title":"Design and Synthesis of a Novel Family of Triazine-Based Inhibitors of Sorbitol Dehydrogenase with Oral Activity: 1-{4-[3R,5S-Dimethyl-4-(4-methyl-[1,3,5]triazin-2-yl)-piperazin-1-yl]-[1,3,5]triazin-2-yl}-(R)ethanol","volume":"11","author":"Mylari","year":"2003","journal-title":"Bioorganic Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.bmcl.2019.04.052","article-title":"Novel triazine-based pyrimidines suppress glomerular mesangial cells proliferation and matrix protein accumulation through a ROS-dependent mechanism in the diabetic milieu","volume":"29","author":"Njeim","year":"2019","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1039\/C0MB00089B","article-title":"Novel use of fluorescent glucose analogues to identify a new class of triazine-based insulin mimetics possessing useful secondary effects","volume":"7","author":"Jung","year":"2011","journal-title":"Mol. Biosyst."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"14095","DOI":"10.1039\/C4RA16903D","article-title":"Discovery of Novel 1,3,5-Triazine-Thiazolidine-2,4-Diones as Dipeptidyl Peptidase-4 Inhibitors with Antibacterial Activity Targeting the S1 Pocket for the Treatment of Type 2 Diabetes","volume":"5","author":"Srivastava","year":"2015","journal-title":"RSC Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"103897","DOI":"10.1016\/j.bioorg.2020.103897","article-title":"Synthesis, characterization, inhibition effects, and molecular docking studies as acetylcholinesterase, \u03b1-glycosidase, and carbonic anhydrase inhibitors of novel benzenesulfonamides incorporating 1,3,5-triazine structural motifs","volume":"100","author":"Lolak","year":"2020","journal-title":"Bioorganic Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"118396","DOI":"10.1016\/j.biopha.2025.118396","article-title":"Carbonic anhydrases inhibition in the management of cardiovascular and cardiometabolic disorders","volume":"190","author":"Mallia","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Cao, H., Liao, S., Zhong, W., Xiao, X., Zhu, J., Li, W., Wu, X., and Feng, Y. (2017). Synthesis, Characterization, and Biological Evaluations of 1,3,5-Triazine Derivatives of Metformin Cyclization with Berberine and Magnolol in the Presence of Sodium Methylate. Molecules, 22.","DOI":"10.3390\/molecules22101752"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"150","DOI":"10.12923\/cipms-2025-0024","article-title":"Methodological approaches for inducing diabetes-like metabolic conditions in zebrafish larvae","volume":"38","author":"Kurach","year":"2025","journal-title":"Curr. Issues Pharm. Med. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1900\/RDS.2020.16.13","article-title":"Recent Advances in In-Vitro Assays for Type 2 Diabetes Mellitus: An Overview","volume":"16","author":"Vhora","year":"2020","journal-title":"Rev. Diabet. Stud."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1018\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T10:26:28Z","timestamp":1782815188000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":88,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071018"],"URL":"https:\/\/doi.org\/10.3390\/ph19071018","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]}}}